- Home
- HYFM vs BIVI Comparison
HYFM vs BIVI Comparison
Compare HYFM & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- BIVI
- Stock Information
- Founded
- HYFM 1977
- BIVI 2013
- Country
- HYFM United States
- BIVI United States
- Employees
- HYFM N/A
- BIVI N/A
- Industry
- HYFM Industrial Machinery/Components
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- HYFM Industrials
- BIVI Health Care
- Exchange
- HYFM Nasdaq
- BIVI Nasdaq
- Market Cap
- HYFM 22.8M
- BIVI 18.8M
- IPO Year
- HYFM 2020
- BIVI N/A
- Fundamental
- Price
- HYFM $2.29
- BIVI $0.84
- Analyst Decision
- HYFM Hold
- BIVI Strong Buy
- Analyst Count
- HYFM 2
- BIVI 1
- Target Price
- HYFM $7.00
- BIVI $30.00
- AVG Volume (30 Days)
- HYFM 874.6K
- BIVI 204.2K
- Earning Date
- HYFM 05-13-2025
- BIVI 05-13-2025
- Dividend Yield
- HYFM N/A
- BIVI N/A
- EPS Growth
- HYFM N/A
- BIVI N/A
- EPS
- HYFM N/A
- BIVI N/A
- Revenue
- HYFM $190,288,000.00
- BIVI N/A
- Revenue This Year
- HYFM $5.45
- BIVI N/A
- Revenue Next Year
- HYFM $5.33
- BIVI N/A
- P/E Ratio
- HYFM N/A
- BIVI N/A
- Revenue Growth
- HYFM N/A
- BIVI N/A
- 52 Week Low
- HYFM $1.50
- BIVI $0.62
- 52 Week High
- HYFM $10.30
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- HYFM 42.50
- BIVI 43.29
- Support Level
- HYFM $1.51
- BIVI $0.75
- Resistance Level
- HYFM $2.49
- BIVI $0.89
- Average True Range (ATR)
- HYFM 0.32
- BIVI 0.12
- MACD
- HYFM 0.13
- BIVI 0.02
- Stochastic Oscillator
- HYFM 49.38
- BIVI 64.96
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.